RHYTHM PHARMACEUTICALS, INC. (RYTM) Spending and interest coverage
- R&D / revenue · 12 months: Value 72.20%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 36.36%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 72.20% | Research and development expense / revenue. Period ending 2026-06-30. $173.21M ÷ $239.92M × 100 ≈ 72.20% |
| Stock-based compensation / revenue · 12 months | 36.36% | Share-based compensation / revenue. Period ending 2026-06-30. $87.23M ÷ $239.92M × 100 ≈ 36.36% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 173.21M USD | Research and Development Expense |
| Revenue | 239.92M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 87.23M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -200.63M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $173.21M | $239.92M | $87.23M | $-200.63M | (m) | 72.20% | 36.36% | (m) | (m) |
| 2026-03-31 | $172.09M | $217.16M | $77.06M | $-197.37M | (m) | 79.24% | 35.48% | (m) | (m) |
| 2025-12-31 | $167.34M | $189.76M | $66.82M | $-192.02M | (m) | 88.19% | 35.21% | (m) | (m) |
| 2025-09-30 | $166.47M | $174.33M | $58.11M | $-186.21M | (m) | 95.49% | 33.33% | (m) | (m) |
| 2025-06-30 | $158.38M | $156.29M | $50.30M | $-177.44M | (m) | 101.34% | 32.18% | (m) | (m) |
| 2025-03-31 | $146.26M | $136.86M | $44.78M | $-172.62M | (m) | 106.87% | 32.72% | (m) | (m) |
| 2024-12-31 | $237.96M | $130.13M | $39.68M | $-265.50M | (m) | 182.87% | 30.50% | (m) | (m) |
| 2024-09-30 | $226.68M | $112.53M | $37.80M | $-265.51M | (m) | 201.44% | 33.59% | (m) | (m) |
| 2024-06-30 | $222.32M | (m) | $35.41M | $-265.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $225.67M | (m) | $33.94M | $-271.71M | $15.59M | (m) | (m) | -17.43× | Reported |
| 2023-12-31 | $134.95M | $77.43M | $32.55M | $-184.36M | $13.89M | 174.29% | 42.04% | -13.27× | Reported |
| 2023-09-30 | $128.61M | (m) | $29.17M | $-185.19M | $12.35M | (m) | (m) | -14.99× | Reported |
| 2023-06-30 | $116.15M | (m) | $25.35M | $-180.50M | $11.60M | (m) | (m) | -15.55× | Reported |
| 2023-03-31 | $114.06M | (m) | $21.60M | $-179.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $108.63M | (m) | $19.83M | $-179.16M | $5.20M | (m) | (m) | -34.45× | Reported |
| 2022-09-30 | $116.66M | (m) | $19.22M | $-188.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $123.08M | (m) | $19.69M | $-193.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $116.73M | (m) | $20.22M | $-188.35M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $104.13M | (m) | $20.80M | $-170.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $94.51M | (m) | $20.39M | $-154.14M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $89.96M | (m) | $19.81M | $-144.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $87.86M | (m) | $17.17M | $-135.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $90.45M | (m) | $17.45M | $-136.57M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $93.31M | (m) | $16.12M | $-135.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $96.88M | (m) | $14.46M | $-138.55M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $109.19M | (m) | $14.71M | $-150.78M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $109.45M | (m) | $11.88M | $-146.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $103.40M | (m) | $10.97M | $-138.93M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $87.54M | (m) | $9.83M | $-121.06M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $60.81M | (m) | $8.08M | $-91.94M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $50.34M | $0.00 | $6.39M | $-78.42M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $38.23M | (m) | $5.08M | $-62.25M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $33.49M | (m) | $4.05M | $-51.29M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $30.31M | (m) | $2.97M | $-43.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $22.89M | $0.00 | $2.28M | $-32.41M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $19.59M | $0.00 | $1.17M | $-25.91M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $7.15M | (m) | $298.00K | $-10.57M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |